Prestwick3_000009

Synopsis, Chemistry

APIs // Active Pharmaceutical Ingredients

57 Suppliers, 31 USDMF, 22 CEP/COS, 8 JDMF, 10 EU WC, 17 KDMF, 17 NDC API, 24 Listed Suppliers

DEVELOPMENTS

2 Drug(s) in Development

2 Drug(s) in Development

PRICE INFORMATION

API Reference Price, API Exports, API Imports, FDF Exports, FDF Imports

INTERMEDIATES

2 Suppliers

2 Suppliers

DOSSIERs // Finished Dosage Forms

3052 Dossiers, 874 FDA Orange Book, 1374 Europe, 235 Canada, 23 Australia, 161 South Africa, 385 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 25MG;25MG, TABLET;ORAL - 50MG;50MG, CAPSULE;ORAL - 25MG;37.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 25MG;37.5MG, TABLET;ORAL - 50MG;75MG, TABLET;ORAL - 10MG;25MG, TABLET;ORAL - 5MG;12.5MG, TABLET;ORAL - 12.5MG;10MG, TABLET;ORAL - 12.5MG;20MG, TABLET;ORAL - 25MG;20MG, TABLET;ORAL - 12.5MG;100MG, TABLET;ORAL - 12.5MG;50MG, TABLET;ORAL - 25MG;100MG, CAPSULE;ORAL - 12.5MG, TABLET;ORAL - 12.5MG;150MG, TABLET;ORAL - 12.5MG;300MG, TABLET;ORAL - 12.5MG;75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 25MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - 12.5MG;160MG, TABLET;ORAL - 12.5MG;320MG, TABLET;ORAL - 12.5MG;80MG, TABLET;ORAL - 25MG;160MG, TABLET;ORAL - 25MG;320MG, TABLET;ORAL - 16MG;12.5MG, TABLET;ORAL - 32MG;12.5MG, TABLET;ORAL - 32MG;25MG, TABLET;ORAL - 12.5MG;40MG, TABLET;ORAL - 12.5MG;80MG, TABLET;ORAL - 25MG;80MG, TABLET;ORAL - 12.5MG;20MG, TABLET;ORAL - 12.5MG;40MG, TABLET;ORAL - 25MG;40MG, TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 100MG TARTRATE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 25MG TARTRATE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 50MG TARTRATE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 150MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 300MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 300MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**, TABLET;ORAL - EQ 10MG BASE;12.5MG;160MG, TABLET;ORAL - EQ 10MG BASE;25MG;160MG, TABLET;ORAL - EQ 10MG BASE;25MG;320MG, TABLET;ORAL - EQ 5MG BASE;12.5MG;160MG, TABLET;ORAL - EQ 5MG BASE;25MG;160MG, TABLET;ORAL - 25MG, TABLET;ORAL - 50MG

RELATED EXCIPIENT COMPANIES

Suppliers, 39 Kerry, 39 BASF, 29 Roquette, 25 SPI Pharma, 20 Microlex e.U, 16 Seppic, 14 Nanjing Well Pharmaceutical, 13 Gangwal Healthcare, 13 Gangwal Chemicals, 13 Corel Pharma Chem, 12 Sigachi Industries, 12 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 10 Actylis, 9 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 8 Boai NKY Pharmaceuticals Ltd, 7 DFE Pharma, 7 Ideal Cures Pvt Ltd, 6 Lonza Capsugel, 6 Prachin Chemical, 6 Vasa Pharmachem, 5 Ingredion Pharma Solutions, 5 Pharmatrans-Sanaq, 4 Kima Chemical, 4 ACG Worldwide, 4 Alcedo Pharmachem, 4 DKSH, 3 The Dow Chemical Company, 3 Ulanqab Kema New Material, 3 Finar, 3 Clariant, 3 Jai Radhe Sales, 3 Rochem International Inc, 2 Seqens, 2 Shijiazhuang Huaxu Pharmaceutical, 2 Pfanstiehl, 2 Nanjing Bold Chemical, 2 Qualicaps, 2 Nomisma Healthcare, 1 Avesta Pharma, 1 Zhejiang Huakang Pharmaceutical, 1 Minakem, 1 Qianhao Chemical (Hebei) Co., Ltd, 1 Aeon Procare, 1 Huzhou Sunflower Pharmaceutical Co. Ltd, 1 Vertellus, 1 Evonik, 1 Shanghai Welltone Material Technology Co., Ltd, 1 Doshion Polyscience, 1 NEWEDGE Overseas, 1 Chynops Pharma, 1 Pharm-RX Chemical

EXCIPIENTS BY APPLICATIONS

105 Fillers, Diluents & Binders, 60 Coating Systems & Additives, 55 Direct Compression, 50 Disintegrants & Superdisintegrants, 39 Granulation, 38 Controlled & Modified Release, 37 Solubilizers, 37 Lubricants & Glidants, 32 Film Formers & Plasticizers, 31 Thickeners and Stabilizers, 29 Taste Masking, 29 Topical, 28 Parenteral, 21 Chewable & Orodispersible Aids, 19 Co-Processed Excipients, 10 API Stability Enhancers, 10 Emulsifying Agents, 9 Empty Capsules, 6 Surfactant & Foaming Agents, 5 Rheology Modifiers, 4 Vegetarian Capsules, 2 Coloring Agents, 1 Soft Gelatin

GLOBAL SALES INFORMATION

94 US Medicaid Prescriptions, 1308 Finished Drug Prices

MARKET PLACE

29 APIs, 18 DOSSIERS // FDF

PATENTS

4 US Patents

4 US Patents

ANALYTICAL SOLUTION(s)

2 BioAnalytical Methods, 3 EDQM Standards, 1 USP Standards, 3 JP Standards, 1 Other Ref. Standards

DIGITAL CONTENT

3 Data Compilation & Company Tracker #PharmaFlow, 143 News

Annual Sales of Prestwick3_000009 reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

Prestwick3_000009

Synopsis

Chemistry

APIs // Active Pharmaceutical Ingredients

57 Suppliers

31 USDMF

22 CEP/COS

8 JDMF

10 EU WC

17 KDMF

17 NDC API

24 Listed Suppliers

DEVELOPMENTS

2 Drug(s) in Development

PRICE INFORMATION

API Reference Price

API Exports

API Imports

FDF Exports

FDF Imports

INTERMEDIATES

2 Suppliers

DOSSIERs // Finished Dosage Forms

3052 Dossiers

874 FDA Orange Book

1374 Europe

235 Canada

23 Australia

161 South Africa

385 Listed Dossiers

DRUG PRODUCT COMPOSITION

TABLET;ORAL - 25MG;25MG

TABLET;ORAL - 50MG;50MG

CAPSULE;ORAL - 25MG;37.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 25MG;37.5MG

TABLET;ORAL - 50MG;75MG

TABLET;ORAL - 10MG;25MG

TABLET;ORAL - 5MG;12.5MG

TABLET;ORAL - 12.5MG;10MG

TABLET;ORAL - 12.5MG;20MG

TABLET;ORAL - 25MG;20MG

TABLET;ORAL - 12.5MG;100MG

TABLET;ORAL - 12.5MG;50MG

TABLET;ORAL - 25MG;100MG

CAPSULE;ORAL - 12.5MG

TABLET;ORAL - 12.5MG;150MG

TABLET;ORAL - 12.5MG;300MG

TABLET;ORAL - 12.5MG;75MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 25MG;300MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - 12.5MG;160MG

TABLET;ORAL - 12.5MG;320MG

TABLET;ORAL - 12.5MG;80MG

TABLET;ORAL - 25MG;160MG

TABLET;ORAL - 25MG;320MG

TABLET;ORAL - 16MG;12.5MG

TABLET;ORAL - 32MG;12.5MG

TABLET;ORAL - 32MG;25MG

TABLET;ORAL - 12.5MG;40MG

TABLET;ORAL - 12.5MG;80MG

TABLET;ORAL - 25MG;80MG

TABLET;ORAL - 12.5MG;20MG

TABLET;ORAL - 12.5MG;40MG

TABLET;ORAL - 25MG;40MG

TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 100MG TARTRATE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 25MG TARTRATE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 50MG TARTRATE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 150MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 150MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 300MG BASE;12.5MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 300MG BASE;25MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**

TABLET;ORAL - EQ 10MG BASE;12.5MG;160MG

TABLET;ORAL - EQ 10MG BASE;25MG;160MG

TABLET;ORAL - EQ 10MG BASE;25MG;320MG

TABLET;ORAL - EQ 5MG BASE;12.5MG;160MG

TABLET;ORAL - EQ 5MG BASE;25MG;160MG

TABLET;ORAL - 25MG

TABLET;ORAL - 50MG

RELATED EXCIPIENT COMPANIES

Suppliers

CAPSULE;ORAL - 25MG;37.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 12.5MG;75MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - 25MG;300MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 100MG TARTRATE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 25MG TARTRATE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET, EXTENDED RELEASE;ORAL - 12.5MG;EQ 50MG TARTRATE Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 150MG BASE;12.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 150MG BASE;25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 300MG BASE;12.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons

TABLET;ORAL - EQ 300MG BASE;25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons